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Abstract 
Diabetes is one of the most common chronic diseases in the world and its 
incidence is on the rise. Maintenance of continuous normoglycaemic conditions 
is the key goal for the management of both type 1 and type 2 diabetes in 
patients. Glucose responsive insulin delivery (GRID) systems have the potential 
to act as artificial pancreas as they can modulate the insulin release relative to 
external glucose concentrations. GRIDs can not only achieve tighter glycaemic 
control by preventing both hypo- and hyperglycaemia, but also eliminate the 
need for frequent finger-stick glucose tests and multiple daily insulin injections. 
In this research, we examined the selectivity of and insulin release from two 
boronic acids (2-formyl-3-thienylboronic acid (FTBA) and 4-formylphenylboronic 
acid (FPBA)) to glucose when conjugated to chitosan as nanoparticles. Adsorption 
of glucose to BA: chitosan conjugates was dose-dependent up to 1:1 at 35 and 
42% for FPBA and FTBA respectively but the FTBA conjugates adsorbed more 
glucose and fructose at respective FPBA ratios. The affinity of both BA conjugates 
to glucose decreased with increase in BA ratio. On the other hand, the affinity 
of both BA conjugates for fructose decreased from ratio 1:1 to 2:1 then rose 
again at 3:1. Insulin release from FPBA nanoparticles (FPBAINP) and FTBA 
nanoparticles (FTBAINP) were both concentration-dependent within 
glyceamically relevant values (1-3mg/ml glucose and 0.002mg/ml fructose). 
Furthermore, the total amounts of insulin released from FPBAINP in both the 
media were higher than from FTBAINP. Both FPBAINP and FTBAINP have the 
potential for development as a glucose-selective insulin delivery system in 
physiological settings. 
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CHAPTER 1 
BACKGROUND AND OBJECTIVES 
1.1. Overview of diabetes 
Diabetes mellitus is a medical disorder involving high blood glucose levels – 
hyperglycaemia [1]. As one of the most common chronic diseases in almost every 
country in the world, the incidence of diabetes is on the rise. The number of 
diabetic patients is expected to cross 400 million [2] and the total worldwide 
health expenditure for diabetes is estimated to be in excess of US$560 billion 
per year by 2030 [3]. This shows how much of an economic burden diabetes poses 
to be for national healthcare systems globally. Diabetes mellitus is broadly 
categorised into the three most common types – type 1, type 2, and gestational 
diabetes. 
Type 1 diabetes, formerly known as juvenile diabetes, is usually diagnosed in 
children and young adults, although it can appear at any age. It accounts for 10% 
of all diabetes mellitus cases. Type 1 diabetes is the result of insulin deficiency 
in the body which is caused by an autoimmune condition in the affected 
individuals, whereby insulin-producing β-cells in the pancreas are destroyed by 
T-cells, eventually leading to hyperglycaemia [4]. People with type 1 diabetes 
need to take insulin every day to stay alive. 
Type 2 diabetes is often categorized as a ‘lifestyle disease’ and manifests as a 
result of the body’s inability to effectively utilise insulin (insulin resistance) and 
lack of insulin production, leading to high blood glucose levels. This form of 
diabetes is often associated with lack of physical activity and obesity [5]. For 
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type 2 diabetes, initial treatment focuses on delaying disease progression via 
exercise and control of meals. Furthermore, patients are prescribed oral and/or 
injectable medications to improve their insulin production and function. 
However, insulin is required as the body’s own insulin production diminishes 
eventually. 
Gestational diabetes develops in some pregnant women, however, most of the 
time, this type of diabetes goes away after the baby is born. People with 
gestational diabetes have a greater chance of developing type 2 diabetes later 
in life. Sometimes diabetes diagnosed during pregnancy is actually type 2 
diabetes. 
1.2. Clinical manifestations of diabetes 
Typical symptoms of diabetes are listed as follows: 
 Increased frequency of urination 
 Excessive thirst 
 Extreme hunger – even though patient is having sufficient food 
 Feeling very tired all the time 
 Cloudy vision 
 Slow healing of minor injuries 
 Unexplained weight loss even though patient is eating more 
 Tingling or numbness in the hands and/or feet 
Some people may experience only a few of the symptoms listed above. A lot of 
people with type 2 diabetes experience very mild to no symptoms and hence 
remain incognizant of their medical condition.  
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1.3. Insulin 
It is a 51-amino acid polypeptide hormone produced by the β-cells of the islets 
of Langerhans in the pancreas. The amino acids are distributed in two chains of 
21 and 30 amino acids. The chains are linked together by two disulphide bridges. 
Insulin controls the glucose levels in blood by inducing the liver and muscle cells 
to take up glucose from the blood [6]. In type 1 diabetes, an autoimmune 
response causes the destruction of β-cells by T-cells which leads to insulin 
deficiency and high blood glucose levels. Insulin, like other proteins and 
peptides, is unstable in the gastrointestinal tract and hence oral delivery is not 
feasible. Consequently, subcutaneous injections of insulin are used [7] 
1.4. Current treatment options for diabetes 
Early detection and treatment of diabetes can reduce the risk of developing the 
complications of diabetes. Maintenance of continuous normoglycaemic 
conditions (70–140 mg per dl or 4–8 mM of glucose) is the key goal for the 
management of both type 1 and type 2 diabetes in patients [8]. This level of 
glucose is currently managed by subcutaneous injections, usually by the patients 
themselves or by trained professionals. Hyperglycaemia (high blood glucose 
levels), if left untreated for a prolonged period of time, can lead to medical 
complications such as blindness, heart and kidney failure, nerve degeneration, 
and foot ulceration leading to amputation [9]. Contrarily, an excess of insulin in 
blood can lead to hypoglycaemia (low blood glucose levels) which can result in 
seizures, unconsciousness or even death [10]. 
Insulin replacement therapy is prescribed for the management of Type 1 diabetes 
[11]. For type 2 diabetes, lifestyle changes and oral medications are the initial 
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modes of treatment to improve insulin production and function [1]. However, as 
the body’s natural insulin production gradually declines, insulin replacement 
therapy is eventually necessary to control blood glucose levels [6]. Typical insulin 
treatment involves injections of fast-acting insulin during mealtimes, followed 
by longer-acting insulin injections which maintain a baseline insulin level 
throughout the day [11,12].  
Subcutaneous injections of insulin are painful and cumbersome leading to poor 
patient compliance. Furthermore, this form of insulin therapy is ‘open-loop’, 
which means that the insulin doses are determined by the history of the patients’ 
blood glucose profile after various meals and insulin treatments [13]. All these 
make it extremely difficult to maintain ideal blood glucose levels throughout the 
day. Future insulin therapies need to be glucose-regulated, less painful, 
relatively inexpensive to manufacture and easily available for administration in 
clinical settings [14]. Currently, scientists are working towards achieving these 
goals by exploring other routes of insulin delivery [15], modulating the 
pharmacokinetics of insulin [11] and formulating other therapeutics [16]. 
1.4.1. Improved technologies for insulin replacement therapy 
Several technologies have recently been developed to overcome the above-
mentioned challenges of insulin replacement therapy. Pickup reported an insulin 
pump which can be worn externally and is composed of an insulin depot 
connected to a subcutaneously implanted cannula. The depot can be replaced 
when necessary and the pump can be adjusted to deliver both a bolus dose of 
insulin for mealtimes, and a basal dose throughout the day [14]. Another recent 
invention is the microcomputer-programmed insulin pump that comes with a 
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continuous glucose monitor (CGM) [17]. The CGM, which is linked directly to the 
pump, can be used to calculate the correct insulin dosage. The pump can then 
inject the required amount of insulin, thus providing a glucose-dependent insulin 
delivery to the patient. 
Even with these innovative technologies to improve patient compliance and 
maintain tight glycaemic control required in patients, there are several 
disadvantages. The insulin pumps need to be replaced and maintained frequently 
for proper functioning which is costly. Furthermore, the implantation of sensors 
and cannulas are invasive and present the risk of infection and inflammation as 
the body considers these as foreign objects [14]. 
1.4.2. Alternative routes of insulin delivery 
Oral route is the preferred route of drug delivery, however, it is not feasible to 
deliver protein and peptide drugs such as insulin. The bioavailability of insulin 
via this route is low due to its instability in acidic conditions, enzymatic 
degradation and insufficient permeability across the gastrointestinal mucosa 
[18]. As a result, researchers are exploring alternative routes of insulin delivery. 
Besides subcutaneous route, the intranasal and pulmonary routes are being 
increasingly investigated.  
The nasal cavity has a large surface area-to-volume ratio for absorption of drugs. 
Furthermore, the high vascularity of the nasal mucosa means that the absorbed 
drugs are rapidly cleared from the site of absorption. This ensures fast and direct 
entry of drugs into the systemic circulation, avoiding the hepatic first-pass 
metabolism [19]. Despite the potential of the nasal route, there are a number of 
factors that limit the efficient absorption and systemic delivery of peptide drugs. 
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Continuous mucociliary clearance, presence of proteolytic enzymes and low 
permeability of the nasal epithelia are the main constraints that limit the 
systemic bioavailability of insulin following intranasal administration [20,21]. 
The respiratory tree offers great promise as the pulmonary route for insulin 
delivery due to its high vascularisation and large surface area. However, factors 
like breathing pattern, lung disease, smoking, and patients’ ability to use 
inhalation devices might limit the efficient systemic delivery of insulin.  
1.5. Nanotechnology in medicine 
In the last two decades, advances in nanotechnology have vastly improved both 
diagnosis and treatments in the field of cancer and cardiovascular biology [22-
25]. Various nanoparticulate formulations such as liposomes, polymer 
nanoparticles, nanostructures, metallic nanoparticles and stimuli-responsive 
nanoparticles have proved to be not only biocompatible but also possess ideal 
physicochemical properties for potential biomedical applications [26-30]. Using 
nanotechnology, drugs can be delivered to the site of action only. In this 
technique, nanoparticles containing the active medicinal ingredient release the 
drug at the morbid region only, hence reducing systemic side-effects and also 
the cost of treatment. Nanoparticles can also be modified to encapsulate 
artificial cells which can be used in tissue engineering to repair damaged cells or 
organs in the body.  
1.5.1. Diabetes management with nanotechnology 
In the recent past, scientists have started exploring the potential of 
nanotechnology for diagnosis, monitoring and treatment of diabetes. Progress in 
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the field of nanotechnology and polymer science can now enable scientists to 
engineer nanoparticles that can release the loaded drug by sensing changes in 
their surroundings [13]. We believe that this would stage the new frontier in 
management of diabetes, taking into account most of the drawbacks associated 
with the current mode of administration as well as the challenges posed when 
considering alternate routes of administration. Whilst we are still very far off, a 
system capable of releasing insulin in response to an increase in blood glucose 
concentration presents the closest we can get in designing an artificial pancreas. 
1.6. Glucose responsive insulin delivery (GRID) 
GRID is a method whereby insulin is released in response to a rise in blood glucose 
levels and the release is stopped when blood glucose goes back to euglycaemic 
levels. These systems have the potential to act as artificial pancreas as they can 
modulate the insulin release relative to external glucose concentrations, hence 
simulating the body’s natural physiological response to changes in blood glucose 
levels. Consequently, these ‘closed-loop’ systems can not only achieve tighter 
glycaemic control by preventing both hypo- and hyperglycaemia, but also 
eliminate the need for frequent finger-stick glucose tests and multiple daily 
insulin injections [31]. Currently, the three most extensively studied glucose 
sensors are glucose oxidase, glucose-binding proteins and glucose-binding small 
molecules. Using these glucose responsive molecules, insulin loaded 
nanoparticles can be formulated which will release the drug via degradation, 
disassembly or swelling in response to changes in blood glucose concentrations 
[32,33]. 
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1.6.1. Glucose oxidase 
It is an enzyme that converts glucose to gluconic acid in the presence of oxygen 
(fig.1.1) and is currently the most widely studied glucose sensor in the literature. 
An early example of the potential use of glucose oxidase for GRID dates back to 
1988 when Fischel-Ghodsian et al. formulated insulin analogues which were 
soluble in acidic pH but insoluble in pH 7.4 (physiological conditions). When 
implanted in the body, high blood glucose levels resulted in acidic conditions 
surrounding the system leading to the release of insulin [34]. More recently, Gu 
et al. have demonstrated insulin release and control of blood glucose in animal 
models from a microgel GRID composed of chitosan, glucose oxidase 
nanocapsules and insulin [35]. Qi et al. and Luo et al. have developed insulin 
containing polymeric nanoparticles that release the drug in acidic conditions 
[36,37]. While glucose oxidase-based systems boast being highly specific, their 
response can sometimes be slow or irregular due to changes in environmental 
temperature and oxygen concentrations. 
 
Fig.1.1. Glucose oxidase-based sensor [13] 
1.6.2. Glucose-binding protein (GBP) 
GBP is an alternative to non-enzymatic GRID. The proteins can be used to 
crosslink polymer chains together to form nanoparticles. Interaction between 
glucose and the proteins results in destabilisation of the nanoparticles and the 
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loaded drug can be released via disassembly or swelling. Brownlee et al. 
demonstrated such a system using the glucose-binding lectin, ConA (fig.1.2) [38]. 
As glucose-binding proteins possess high affinity and specificity for glucose, they 
have continued to gather increasing attention as potential for GRID system. 
However, immunological response to foreign ConA has been the major issue that 
needs to be overcome for their clinical use [39]. 
 
Fig.1.2. GBP-based sensor[13] 
1.6.3. Boronic acids 
Small molecule glucose binders such as boronic acids offer a completely different 
approach to glucose-mediated insulin release. Phenylboronic acids, for instance, 
can be conjugated to or crosslinked between suitable polymers which can then 
be formulated into insulin-loaded nanoparticles. Interaction between glucose 
and boronic acid at high blood glucose concentrations will result in swelling of 
the nanoparticle matrix leading to insulin release (fig.1.3). When the blood 
glucose level goes back to normal, the interaction is reduced and the swelling is 
minised and hence the insulin release. While this chemical system offers the 
advantage of having fast response rates and no immunological response, it lacks 
in specificity as boronic acids can interact with other diols (fructose, in 
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particular) in blood. Research is underway to improve the sensitivity of boronic 
acids to glucose [13].  
 
Fig.1.3. Boronic acid-based sensor 
1.7. Polymer-based nanoparticulate insulin delivery systems 
Evolution in the field of polymer science and drug delivery in the last decades 
have led to better understanding of polymer structure and improved polymeric 
drug delivery systems. In this regard, biodegradable and biocompatible polymers 
serve an added advantage when used in conjunction with drug delivery. Different 
methods and technologies can now be used to prepare polymeric nanoparticles 
depending on the required physicochemical properties for targeted drug 
delivery. Several polymers – both natural and synthetic – have been used to 
prepare insulin loaded nanoparticles for its efficient delivery [40]. An outline of 
the more commonly used polymers in nanodrug delivery follows. 
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1.7.1. PLA nanoparticles 
Poly(lactic acid) (PLA) is a synthetic polyester polymer that is considered 
biocompatible and biodegradable due to the hydrolysis of its monomeric units in 
the body [40]. Xiong et al. developed a pluronic block copolymer (PLA-b-
pluronic-b-PLA) vesicles for oral delivery of insulin [41]. The in vitro release 
study showed a biphasic release profile of insulin from their vesicles. In vivo 
investigation using diabetic mice revealed extended hypoglycaemic effects of 
the insulin vesicles which showed promise to be developed into an orally 
administered formulation. In a more recent study, the same group proved the 
biocompatibility of their vesicles using human ovarian cancer cells [42]. 
1.7.2. PLGA nanoparticles 
Poly(lactic-co-glycolic acid) (PLGA) is an aliphatic copolymer that has been 
widely investigated for drug delivery in general. For example, it has been used 
in insulin delivery due to its biodegradability, biocompatibility and prolonged-
release profiles. PLGA offers additional advantage in that it can be combined 
with other polymers or coated with various ligands to improve encapsulation 
efficiency and the uptake of loaded insulin [40]. Yang et al. formulated PLGA-
loaded insulin nanoparticles and found that insulin was released at a lower rate 
in acidic pH reaching about 90% of release in 11 days. On the other hand, the 
release was faster under physiological conditions since about 90% of the total 
amount of insulin was released in 3 days. In vivo studies involving oral 
administration of the nanoparticles to diabetic rats revealed a decrease in blood 
glucose levels with an increase in blood insulin levels. These results showed the 
extended release properties of PLGA nanoparticles, and their ability to protect 
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insulin and consequently decrease the blood glucose levels when administered 
orally [43]. However, it should be noted that PLA and PLGA nanoparticles have 
an overall negative charge and this property may reduce the uptake of insulin 
nanoparticles through the intestinal membrane, and hence decrease the 
bioavailability of oral formulations of insulin. 
1.7.3. Dextran nanoparticles 
Dextran is a polysaccharide made up of α-D-glycose units that bind to each other 
through glycosidic bonds. Since it is a natural polymer, it has high 
biocompatibility and biodegradability in the body [40]. Chalasani et al. 
formulated insulin containing dextran nanoparticles by an emulsion method. The 
encapsulation efficiency of the system was between 45 and 70% and from that, 
65 to 83% of insulin remained protected from the grastrointestinal proteases. In 
vitro release experiments showed an extended release of up to 95% within 48hr, 
while the in vivo test resulted in a plasma glucose level decrease from 70 to 75% 
after 5hr of oral administration, reaching basal levels in 8–10hr which was then 
sustained for 54hr [44]. 
1.7.4. Chitosan nanoparticles 
Among the natural polymers, chitosan is the most widely used for insulin delivery 
because of its high biocompatibility, biodegradability, non-toxicity and 
hydrophilicity. Furthermore, it is relatively simple and easy to prepare chitosan 
nanoparticles via dropwise addition of a suitable cross linker such as 
tripolyphosphate or via polyelectrolyte complexation with insulin on its own. As 
the nanoparticles form spontaneously in aqueous media with high encapsulation 
efficiency, there is no need for additional solvents or heating, hence eliminating 
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concerns of cytotoxicity and insulin instability. These are some of the main 
advantages of chitosan over other polymers [45,46]. Pan et al. proved that 
chitosan nanoparticles are able to enhance the intestinal absorption of insulin. 
The encapsulation efficiency of their nanoparticles was up to 80% and the release 
profile of insulin manifested an initial burst release phase which depended on 
the pH of the environment. When administrated in vivo, insulin-loaded chitosan 
nanoparticles resulted in hypoglycemia for 15hr with about 15% higher 
bioavailability of insulin compared to that after subcutaneous administration of 
insulin [47]. 
1.8. Objectives of the research 
For a GRID system to present as an artificial pancreas, it should ideally be 
implanted only once inside the body. However, as discussed before, the current 
insulin pumps need frequent replenishment and hence the surgical implantation 
has to be carried out regularly. 
In this research, we aim to formulate a GRID system that can be used to deliver 
substantial quantities of the drug with hopefully a lesser dosing frequency. 
Nanoparticles are chosen as the delivery carrier because of the high surface area-
to-volume ratio, which means that the response time for the delivery of insulin 
when in contact with glucose is rapid. The large surface area also allows us to 
improve the payload. Our primary objective is to formulate a novel polymeric 
glucose responsive insulin-containing nanoparticulate system using boronic acid 
as the glucose sensor. The chosen polymer is chitosan and the boronic acid is 2-
formyl-3-thienylboronic acid. It is hypothesised that the formulated GRID system 
can be used to deliver insulin on a repeated basis via transdermal patches, depot 
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injections, inhalable devices or even oral routes. This will eliminate the need for 
repeated invasive surgical procedures, while at the same time significantly 
improving overall glycaemic control of insulin therapy.  
To achieve the primary goal, specific objectives that would ensure that the 
system functions properly are outlined below: 
 To conjugate the boronic acid to chitosan 
 To characterise the resulting conjugates 
 To formulate the conjugates into a nanoparticulate GRID system 
 To characterise the nanoparticulate GRID system 
 To test the efficiency of the formulated GRID system in vitro 
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CHAPTER 2 
SYNTHESIS AND CHARACTERISATION OF CHITOSAN-
BORONIC ACID CONJUGATES 
2.1. Introduction 
The capability of boronic acids (BAs) to act as chemosensors in biological systems 
is evident from the increasing number of literature in this particular field of 
research. Saccharides are one of the primary target species for boronic acid 
interactions. These polyhydroxyl entities of saccharides have “high solvation 
enthalpies in aqueous solutions” and have little structural differences apart from 
their configurations which make them extremely difficult to be distinguished by 
most synthetic chemosensors [48]. This is one of the fundamental reasons as to 
why there has been very little progress in the development of glucose-responsive 
sensors past the clinical stage. As discussed in chapter 1, glucose oxidase and 
glucose-binding proteins such as lectins are currently being widely investigated 
for their potential use as glucose sensors. Notwithstanding, unlike biological 
sensors, synthetic sensors are cheaper, more stable and oxygen-independent 
which makes them more attractive. Boronic acids (BAs) are promising candidates 
as synthetic sensors for glucose detection [48]. 
BAs bind reversibly to cis-1,2- or 1,3-diols via covalent interactions to form five- 
or six-membered cyclic esters. The interaction has been proven to be so strong 
that mM or even sub-mM levels of saccharides in biological systems can bind to 
boronic acids. BAs can distinguish between different saccharides as the strength 
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of binding depends on the positions of the hydroxyl groups. It has now been 
shown that monoboronic acids have the highest selectivity for fructose among 
all the saccharides [49]. This is because the β-D-fructofuranose (fig.2.1a) is the 
form of fructose that binds to boronic acids and is available as 25% of total 
fructose in D2O at 31ºC. On the other hand, with glucose, the α-D-glucofuranose 
(fig.2.1b) form that binds to boronic acids makes up only 0.14% of the total 
glucose in D2O at 27ºC [48]. 
    
(a)      (b) 
Fig.2.1. Structures of (a) fructose and (b) glucose that take part in 
interaction with boronic acids in solution; potential boronic acid binding sites 
are highlighted in blue 
This poses a problem for monoboronic acids to act as glucose-specific sensors for 
systemic insulin delivery because blood has both glucose and fructose and insulin 
release due to the presence of fructose is undesirable in the present context. 
However, the problem can be overcome by using properly positioned 
multiboronic acids. The use of multiboronic acids for glucose-specific response 
is similar to the way biological sensors like lectins work as they have multiple 
binding sites. Multivalency, in chemistry and in biological systems, is a key 
concept which means that when two multivalent (i.e. having more than one 
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binding site) moieties are involved in n binding events (n > 1), the binding occurs 
with higher affinity than the sum of n individual monovalent bindings. According 
to fig.2.1, fructose has one binding moiety while, glucose has two (at the 1,2- 
and 3,5,6-positions). Consequently, monoboronic acids with one binding moiety 
interact with greater affinity with fructose since monovalent interactions take 
place here. However, in di- or multiboronic acids, there are at least two boronic 
acid moieties available for interaction with one glucose molecule, and hence this 
interaction is substantially stronger than monovalent interactions which take 
place with fructose [48].  
   
(a)   (b)    (c)  
Fig.2.2. Structures of (a) FTBA, (b) FPBA and (c) chitosan 
Over the last ten years, scientists have proposed several methods to develop 
glucose-specific boronic acid-based sensors using this concept of multivalency. 
Currently, four main strategies are being widely investigated which include 
synthetic diboronic acids, boronic acid-conjugated polymers, self-assembly of 
simple boronic acids and boronic acid-conjugated nanomaterials [48]. In this 
project, we focus on the covalent attachment of boronic acid to a polymer and 
use this multiboronic acid scaffold as a glucose-specific sensor. We report for 
the first time the use of 2-formyl-3-thienylboronic acid (FTBA) (fig.2.2a) as the 
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boronic acid to be conjugated to a polymer to develop a chemosensor. The 
polymer used is chitosan (fig.2.2c) and the organic reaction used to conjugate 
the boronic acid to chitosan is reductive N-alkylation (fig.2.3). Asantewaa et al. 
used 4-formylphenylboronic acid (FPBA) (fig.2.2b) to prepare chitosan 
conjugates [50] and since it has the same functional group involved in the 
reductive N-alkylation method as FTBA, FPBA was also used in this investigation 
for comparison. The conjugates were extensively examined via various 
spectroscopic methods for evidence of the functionalisation of the BAs to 
chitosan and eventually tested for their glucose specificity.   
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(b) 
Fig.2.3. Reductive N-alkylation between chitosan and (a) FPBA and (b) 
FTBA 
2.2. Materials and methods 
2.2.1. Materials  
Low molecular weight chitosan, 4-formylphenylboronic acid, 2-formyl-3-
thienylboronic acid, sodium borohydride, glucose hexokinase assay kit and 
curcumin were purchased from Sigma Aldrich (St. Louis, MO, USA); acetic acid, 
methanol, acetonitrile, fructose and glucose were purchased from Thermo 
Fischer Scientific (Bridgewater, NJ, USA). All other chemicals were of reagent 
grade. 
2.2.2. Synthesis and purification of boronic acid-chitosan conjugates 
50mg of chitosan (dissolved in 1% acetic acid) and various molar equivalents of 
FPBA and FTBA (Table 2.1) were mixed and stirred in separate clean beakers 
containing 15mls of methanol. After 3 hours, sodium borohydride (1.6 x the molar 
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equivalences of FPBA and FTBA) was added in respective beakers and the 
mixtures were allowed to stir for a further 10 minutes. Afterwards, the reaction 
was quenched with 1M sodium hydroxide. The precipitates formed were 
centrifuged at 1610g for 10mins and washed thoroughly with methanol, ethanol 
and water to remove any unreacted BAs. The conjugates were then lyophilised 
and stored in 2oC for use in further studies. 
  Boronic acid:chitosan 
  0.5:1 (F1) 1:1 (F2) 1.5:1 (F3) 2:1 (F4) 3:1 (F5) 
Chitosan (mg) 50 
FPBA (mg) 23.3 46.6 69.9 93.2 139.8 
FTBA (mg) 24.2 48.4 72.6 96.8 145.2 
NaBH4 (mg) 9.4 18.8 28.2 37.6 56.4 
Table 2.1. Variations of FPBA and FTBA used to formulate conjugates 
2.2.3.  Fourier transform infrared spectroscopy (FTIR) analyses 
The FTIR spectra of pure chitosan, FPBA- and FTBA-chitosan conjugates were 
obtained via a Perkin Elmer FTIR Spectrometer (RX1 S/N 74041, US). Freeze-
dried conjugates were mixed with KBr at a ratio of 1:99 and the mixture ground 
to fine powder using a mortar and pestle. The powder was compressed into a 
disc at 5000 psi for 5 min using a pneumatic press and infra-red spectra collected 
in the range of 2000-400 cm−1. 
2.2.4. Differential scanning calorimetry (DSC) analyses 
The DSC thermograms were obtained using a Mettler Tolledo DSC (UK) system. 
About 5 mg of freeze-dried conjugate was placed in the sample pan, while, the 
reference pan was a standard aluminum pan. Both sample and reference pans 
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were heated from 25ºC to 350ºC at a heating rate of 10ºC/min under 20 mL/min 
purge of nitrogen gas. 
2.2.5. Glucose adsorption studies 
Besides FTIR and DSC, HPLC analyses were carried out to confirm the conjugation 
of BAs to chitosan through glucose adsorption estimation. It is an indirect method 
that relies on the principle of glucose-boronic acid interaction. Pure chitosan 
will adsorb very little to no glucose, however, boronic acid conjugated chitosan 
will adsorb glucose due to the interactions between boronic acid and the 
hydroxyl moieties of glucose. In this investigation, 10mg of pure chitosan 
(control) and 10mg of the various ratios of conjugates were exposed to 1ml of 
5mg/ml glucose solution (prepared with milli-Q water, pH 5.5) in eppendorf 
tubes separately. The tubes were placed in an incubator shaker at 100rpm and 
37ºC for 1hr of equilibration. Afterwards, the mixtures were centrifuged at 4472g 
for 2mins and the supernatants collected to determine the amount of glucose 
present via HPLC. The amount present in the supernatant subtracted from the 
original amount present in the tubes would give the amount of glucose adsorbed 
by the conjugates. Since two different boronic acids are investigated in this 
project, this analysis will also give an indication of the extent of selectivity 
between the two types of conjugates for glucose. 
It is extremely challenging to directly determine glucose via UV-spectroscopy 
hence glucose hexokinase reagent was used for an indirect estimation. In this 
reaction, glucose hexokinase phosphorylates glucose to glucose-6-phosphate 
(G6P) which in turn is oxidised to 6-phosphogluconate (6PG) by glucose-6-
phosphate dehydrogenase (G6PD). During the latter reaction, NAD+ is reduced to 
29 
 
NADH which can be determined via UV-spectroscopy at 340nm. Since the amount 
of NADH produced is directly proportional to the amount of glucose used for the 
entire reaction, the hexokinase assay can give us an estimate of the amount of 
glucose adsorbed by the conjugates.  The following reactions summarise the 
events that take place during the hexokinase assay:  
Glucose + ATP                                     G6P + ADP 
G6P + NAD+                                         6PG + NADH + H+ 
HPLC analysis was carried out by first preparing six different standard solutions 
of glucose ranging from 0.25 – 10mg/ml. 10µl of each of the glucose solutions 
was mixed with 1ml of hexokinase reagent (in excess) in HPLC vials. The 
parameters for the HPLC analysis are as follows: 
 mobile phase – 20mM potassium dihydrogen phosphate and acetonitrile in 
the ratio 95:5 
 elution – isocratic with a flow rate of 1ml/min 
 injection volume – 20µl 
 detection wavelength – 340nm 
 column – Phenomenex Jupiter® C18 with with particle size of 5 μm and 
pore size of 300Å 
A calibration curve of average peak area against glucose concentration was 
plotted and the R2 value and the equation of the line determined. To calculate 
the glucose adsorption of the conjugates, 10µl of the supernatant from the 
samples were equilibrated with 1ml of hexokinase and the above procedure was 
followed to determine the absorbance.  
G6PD 
Hexokinase 
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2.2.6. Investigation of boronic acid selectivity for diols (glucose and fructose) 
The affinities of the two boronic acids for glucose and fructose were studied 
using a different HPLC analysis. This is an indirect but a novel way of determining 
the selectivity of the conjugates for the diols. Springsteen et al. used a dye called 
Alizarin Red S (ARS) to determine the affinities of PBA for various diols [51]. In 
this project, curcumin was used as the dye for the same purpose. The method is 
based on the premise that curcumin reacts with boronic acids in solution to form 
a complex called rosocyanine (fig.2.4).  
 
Fig.2.4. Rosocyanine complexes of varying boronic acid concentrations 
During this reaction, the colour changes from yellow (curcumin) to bright red 
(rosocyanine) and both the colour intensities can be determined 
spectrophotometrically [52]. In this project, 10mg of the conjugates (ratios 1:1, 
2:1 and 3:1) were equilibrated with 1ml of 2mg/ml glucose and fructose solutions 
in eppendorf tubes placed in an incubator shaker at 100rpm and 37ºC. There 
were also control tubes that had the conjugates exposed to 1ml of milli-Q water 
only. After 1hr, 500µl of 0.1mg/ml curcumin solution (dissolved in methanol) was 
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added in each of the tubes and shaken gently for a few seconds. The following 
reactions summarise the events that take place after addition of curcumin: 
Curcumin + conjugate                                            +  
(control) 
Conjugate + diol                                   
+ curcumin       +          +         
(sample)  
In the control, where curcumin is added after exposure of the conjugates to milli-
Q water only, curcumin interacts with all the available boronic acid moieties on 
the solid conjugates at the bottom of the tube. Since curcumin is present in 
excess, there is always free curcumin in solution. In the sample tubes, where the 
conjugates have been equilibrated with glucose or fructose, boronic acid 
moieties interact with the diols with affinities of varying degrees. Consequently, 
fewer boronic acid moieties are available for interaction with curcumin. This 
also means that if the same amount of curcumin (as that in control) is added to 
the sample tubes, the amount of free curcumin in solution will be more in the 
sample tubes. Since curcumin can be detected via UV-spectroscopy at 425nm, 
the difference in the absorbance between the two respective ‘free curcumin’ 
solutions will give an indication of the degree of affinity of the conjugates for 
the two diols. This procedure has not been reported elsewhere. 
The HPLC analysis was carried out by first preparing five standard solutions of 
curcumin ranging from 1 - 50µg/ml. The parameters for the HPLC analysis are as 
follows: 
Curcumin-boronic 
acid complex on the 
conjugates 
Free 
curcumin 
Boronic 
acid-diol 
complex on 
the 
conjugates 
Curcumin-    
boronic acid 
complex on 
the 
conjugates 
Free 
curcumin 
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 mobile phase – acetonitrile, 0.01% acetic acid and methanol in the ratio 
53:42:5  
 elution – isocratic with a flow rate of 1.5ml/min 
 injection volume – 10µl 
 detection wavelength – 425nm 
 column – Agilent Zorbax 300SB-4.6 x 250 mm C18, with particle size of 5 
μm and pore size of 300 Å 
A calibration curve of average peak area against curcumin concentration was 
plotted and the R2 value and the equation of the line determined. To calculate 
the absorbances of ‘free curcumin’ with and without the presence of diols, the 
mixtures were centrifuged at 8765g for 2mins and 10µl of the supernatants were 
injected into the HPLC system. 
2.2.7. Statistical Analysis 
A simple two-tailed t-test was performed with 95% confidence interval to check 
for significant differences between experimental results where necessary. 
2.3. Results and Discussion 
2.3.1. Characterisation of conjugates 
The conjugation of boronic acid to chitosan was confirmed via FTIR, DSC and 
HPLC analysis (involving glucose hexokinase reagent). Fig.2.5a and b show the 
FTIR spectra of FPBA- and FTBA-conjugated chitosan respectively. In both these 
figures, the characteristic peak for chitosan can be seen at around 1650cm-1, 
which is attributed to an amide-linked carbonyl group. In fig.2.5a, the main focus 
should be at the two circled ranges. For pure chitosan, a faint peak can be seen 
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at around 1590cm-1, which is due to the presence of primary amines. However, 
this peak is absent in the spectra of the conjugates, meaning that the bonding 
of boronic acid with FPBA occurs at the primary amine position of the chitosan. 
Another peak which confirms the functionalisation of boronic acid to chitosan is 
that around 830cm-1. This peak manifests when a para-substituted benzene ring 
is involved. Pure chitosan has no such structure, however pure boronic acid does 
and since, the conjugates show peaks at this 830cm-1 region of their spectra, the 
conjugation of boronic acid to chitosan is confirmed [50].  
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(a) 
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(b) 
Fig.2.5. FTIR spectra of pure chitosan and (a) FPBA-chitosan and (b) FTBA-
chitosan conjugates 
36 
 
In fig.2.5b, a similar trend in the spectra at around 1590cm-1 is present to prove 
the conjugation of boronic acid at the primary amine position of the chitosan 
backbone. However, no peak is present at 830cm-1 region of the spectra as FTBA 
does not have a benzene ring nor does the conjugation occur at the para-position 
of the ring. 
Fig.2.6a and b depict the thermograms obtained after the DSC analyses of the 
FPBA and FTBA conjugates. In all the thermograms, an endothermic peak at 
around 100ºC is evident, which can be attributed to the liberation of water from 
the amine and hydroxyl groups within the chitosan backbone. Pure chitosan 
presents an exothermic peak at around 310ºC due to the decomposition of the 
primary amine group. This exothermic peak is also present in the thermograms 
of the conjugates, however, at progressively lower temperatures. Asantewaa et 
al. and Kittur et al. obtained similar thermograms and hypothesised that the 
lower decomposition temperature could be due to the progressive consumption 
of the primary amine groups as more and more boronic acids become conjugated 
to the chitosan backbone [50,53]. 
As discussed in the introduction, HPLC analysis involving glucose hexokinase was 
also carried out to prove the success of the reductive N-alkylation between 
chitosan and the two boronic acids. Fig.2.7a shows a sharp NADH peak at a 
retention time of around 4mins that was obtained from the HPLC analysis of one 
of the glucose standards. The peak is well resolved and free from interfering 
noise. All the glucose samples produced similar chromatograms. The calibration 
curve (fig.2.7b) is a straight line with a regression coefficient close to 1, 
indicating a strong correlation between glucose concentration and the amount 
of NADH produced.  
37 
 
 
(a) 
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(b) 
Fig.2.6. DSC thermograms of pure chitosan and (a) FPBA-chitosan and (b) 
FTBA-chitosan conjugates 
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(a) 
 
(b) 
Fig.2.7. (a) Chromatogram of NADH from glucose standard (10mg/ml) and 
(b) Calibration curve of glucose standards 
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Fig.2.8 shows the percentage glucose adsorption at the various ratios of the two 
boronic acid-chitosan conjugates. Boronic acid is the entity that reversibly binds 
to glucose, hence pure chitosan adsorbs very little to no glucose. Since the 
conjugates have demonstrated glucose adsorption, the conjugation between 
boronic acids and chitosan is once again confirmed. 
It can also be seen that, for both the boronic acids, as the ratio of boronic acid 
to chitosan increases, the glucose adsorption increases up to ratio 1:1. This result 
is similar to those obtained by Asantewaa et al. where they conducted their 
investigation using FPBA only [50]. It can be hypothesised that at ratios below 
1:1, there is only an insufficient number of boronic acids attached to the chitosan 
backbone for glucose adsorption. At ratio 1:1, the number of boronic acids is 
optimum for the maximum adsorption of glucose. Interestingly, at ratios above 
1:1, the number of boronic acid moieties on the chitosan backbone increases, 
however, this also results in an increase in the crystallinity of the conjugates 
[50]. Furthermore, as more and more boronic acids attach to the chitosan 
backbone, the close packing arrangement makes the structure increasingly rigid 
with increased steric hindrance to approaching diols. As the two hydroxyl 
moieties at 1,2- and 3,5,6-positions of α-D-glucofuranose are spread out in 
different directions, a flexible polymer backbone with reasonably spaced boronic 
acid moieties is necessary for effective multivalent binding between boronic 
acids and glucose [48]. This phenomenon might be one of the fundamental 
reasons as to why the adsorption of glucose decreases above the optimum ratio.   
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Fig.2.8. Glucose adsorption of FPBA and FTBA conjugates   
It should also be noted that the FTBA conjugates (at all ratios) had a higher 
percentage of glucose adsorption than their FPBA counterparts (significant at all 
BA:chitosan ratios; p<0.025). In FPBA (fig.2.9a) the chitosan monomers 
conjugate with the boronic acids at position 4 of the phenyl ring, while in FTBA 
(fig.2.9b), the conjugation takes place at position 2 of the thienyl ring. Due to 
the proximity of the thienyl rings of FTBA and the cyclohexane rings of chitosan 
to the glucose molecule as it forms the complex with boronic acid, it can be 
postulated that additional C-H•••π interactions might contribute to a slightly 
higher affinity (and hence greater adsorption) of FTBA to glucose compared to 
that of FPBA.    
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(a)      (b) 
Fig.2.9. Structures of α-glucofuranose complex with (a) FPBA-chitosan and 
(b) FTBA-chitosan conjugates 
2.3.2. Selectivity of boronic acids for glucose and fructose 
The idea of using curcumin to differentiate the affinities of the two boronic acid-
conjugated polymers for glucose and fructose in this project was envisaged to 
explore a novel way of studying the kinetics of adsorption between boronic acids 
and diols. Curcumin can be used to detect boron even at very low (ppm) levels 
[52], so the slightest changes in boronic acid concentrations due to complexation 
between glucose and fructose can be determined using this dye. Fig.2.10a and b 
depict the chromatogram obtained from the HPLC analysis of a curcumin 
standard and the calibration curve of the standards respectively. 
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(a) 
 
(b) 
Fig.2.10. (a) Chromatogram of a curcumin standard (50µg/ml) and (b) 
Calibration curve of curcumin standards 
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The small peaks adjacent to the main curcumin peak belong to 
demethoxycurcumin and bisdemethoxycurcumin. The curcumin standard used in 
this investigation was 98% in content. Considering the very low concentration 
(0.1mg/ml) of curcumin that was used as a dye for the experiments, the 
contribution of the other curcuminoids can be considered negligible. 
As discussed before, an increase in ‘free curcumin’ in solution from a control (no 
diol) sample to that in an experimental (glucose/fructose) sample will indicate 
the complexation between boronic acids and diols. Furthermore, the difference 
in ‘free curcumin’ levels between the diols would give us an understanding of 
the affinity of the boronic acids for glucose and fructose. Fig.2.11 portrays the 
results obtained from this unique investigation. Since it had already been proven 
that the conjugate with boronic acid to chitosan ratio of 1:1 had the highest 
adsorption of glucose (from section 2.3.1), this ratio was chosen for further 
investigation. To further substantiate our hypothesis on the effects of increased 
crystallinity and/or lack of flexibility of the conjugates at higher boronic 
acid:chitosan ratios on the sensitivity of the conjugates to glucose adsorption, 
ratios 2:1 and 3:1 were also chosen for this investigation.  
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(a) 
 
(b) 
Fig.2.11. Selectivity of (a) FPBA-chitosan conjugates and (b) FTBA-chitosan 
conjugates for diols in terms of % increase in ‘free curcumin’ 
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It can be seen that, in the presence of glucose, the amount of free curcumin in 
solution decreases at conjugate ratios above 1:1. This means that at ratios above 
1:1, more curcumin is involved in complexing with boronic acids. So, it can be 
deduced that fewer glucose molecules are occupying the available boronic acid 
binding moieties at higher ratios; in other words, the affinity of the boronic acid-
chitosan conjugates for glucose is decreasing. This observation is in concordance 
with the previous glucose adsorption data in section 2.3.1 and supplements the 
proposition that lack of flexibility in the conjugate backbone at higher boronic 
acid:chitosan ratios might be the principal reason for the decreased affinity of 
glucose.  
Additionally, it should be noted that the % free curcumin in solution at all FTBA 
ratios is significantly higher than those at respective FPBA ratios (p<0.025). 
Hence, it can be affirmed, once again, that FTBA conjugates have higher affinity 
than FPBA conjugates for glucose and the notion that the interactions between 
the thienyl rings (of FTBA), cyclohexane rings (of chitosan backbone) and the 
hydrocarbon skeleton of glucose is the reason behind the higher propensity of 
FTBA for glucose appears to be the plausible explanation. 
The results with fructose are quite interesting and contrasting to that with 
glucose. Here, the affinity of both types of the boronic acid conjugates for 
fructose appears to have decreased from ratio 1:1 to 2:1. SEM studies conducted 
by Asantewaa et al. proved that at ratios above 1:1, the conjugates become less 
porous and more crystalline with flat surfaces [50]. Consequently, with increase 
in crystallinity, the surface area:volume ratio decreases and hence there is less 
interaction between fructose and boronic acids. However, the affinity of boronic 
acid conjugates for fructose rises again at 3:1 which is a contradiction to the 
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theory put forward in the previous sentence. This takes us back to the topic of 
monovalent interactions of fructose with boronic acid (section 2.1). Wu et al. 
identified that fructose acts as a monovalent ligand (fig.2.12) in almost all 
sensing studies performed with boronic acids [48].  
 
Fig.2.12. Monovalent binding between β-fructofuranose and boronic acid-
chitosan conjugate 
Unlike glucose, which has two diol groups involved in multivalent binding with 
two boronic acid moieties and thus requiring a flexible polymer backbone, 
fructose appears to overcome the challenge of increased crystallinity with its 
monovalent interactive option. One molecule of fructose can bind with one 
boronic acid moiety, so at higher conjugate ratios where the number of boronic 
acids attached to chitosan is higher, more fructose molecules come together and 
attach to boronic acids side by side.   
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One final observation that should be made from fig.2.11 is that, at ratio 1:1, the 
selectivity (or affinity) of FPBA conjugates for both the diols is the same; for 
FTBA, the selectivity for glucose is slightly higher (not significant, p>0.025). It 
can be posited that this is the optimum ratio where the conjugates have the 
ideal number of boronic acids for effective multivalent interactions with glucose. 
The sum of the strength of these multivalent interactions is at least equal to that 
of the monovalent interactions between fructose and boronic acids. However, 
we should also note that both the glucose and fructose concentrations in this 
investigation were kept the same (2mg/ml). While this is a realistic glucose 
concentration in biological settings, the fructose concentration in the human 
blood is at least one thousandth less [54,55]. Considering the fact that the 
purpose of this project is to develop a GRID for diabetic patients, it can be 
suggested that both types of boronic acid-chitosan conjugates, designed in the 
present study, are glucose selective at the concentrations studied and likely to 
be so in physiological conditions. 
2.4. Conclusions 
Two different types of boronic acid-chitosan conjugates have been successfully 
prepared and characterised for their glucose sensitivity. Both FPBA- and FTBA-
chitosan conjugates are sensitive to glucose in biologically relevant settings, with 
FTBA possessing slightly higher affinity for glucose. FPBA/FTBA-chitosan ratio of 
1:1 has proved to possess the highest glucose selectivity and will be used to 
conduct insulin nanoparticle formulation and release studies (chapter 3). 
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CHAPTER 3 
INSULIN LOADED BORONIC ACID SENSOR-BASED 
CHITOSAN NANOPARTICLES 
3.1. Introduction 
Biocompatible and biodegradable polymers have attracted much attention by 
formulation scientists in recent years. Advancements in polymer science and 
nanotechnology have made it possible for these polymers to be suitably modified 
with biological and chemical entities for stimuli responsive and targeted drug 
delivery [56-58]. Chitosan is one such polymer which is synthesized through the 
deacetylation of chitin (a natural cellulose derivative commonly present in 
crustaceans such as a crabs and shrimps) in alkaline media. It is mucoadhesive, 
biocompatible and promotes the passage of biomolecules across biological 
epithelia [59]. 
The process of complexing the cationic primary amine groups of chitosan with 
anionic molecules to prepare controlled-release drug formulations has gained 
significant attention in the recent past because of the simplicity of the method. 
Tripolyphosphate (TPP) is the most widely studied polyanion because it is 
nontoxic, can gel quickly, and electrostatically interacts with positively charged 
chitosan. Chitosan-TPP nanoparticles (CSNP) possess several desirable 
physicochemical properties for the delivery of macromolecules and hence have 
proven to be quite attractive in the pharmaceutical industry [60]. Various 
researchers have successfully introduced stimuli-responsive moieties such as 
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concavalin A, glucose oxidase and boronic acids to chitosan with the aim to 
regulate the release of insulin from their delivery systems [61-63]. This pursuit 
fits well with the quest for appropriate management of Type 1 diabetes, which 
necessitates repeated and life-long subcutaneous injections of insulin. In this 
regard, the formulation of a suitable prototype is aimed at reducing the dosing 
frequency of subcutaneous injections as the current option. 
Presently, our aim is to formulate boronic acid-functionalised chitosan 
conjugates into a nanoparticulate GRID system. Various approaches have been 
proposed to encapsulate peptide and protein molecules including ionotropic 
gelation, polyelectrolyte complexation and layer-by-layer adsorption [64-66]. In 
our current investigation, two nanoparticulate insulin delivery systems have 
been prepared via ionotropic gelation with special attention paid to the 
physicochemical properties, encapsulation efficiency and insulin release of the 
delivery systems in response to two main physiological diols (glucose and 
fructose). 
3.2. Materials and methods 
3.2.1. Materials 
Low molecular weight chitosan, sodium tripolyphosphate (TPP), 4-
formylphenylboronic acid, 2-formyl-3-thienylboronic acid and sodium 
borohydride were purchased from Sigma Aldrich (St. Louis, MO, USA); acetic 
acid, methanol, acetonitrile, fructose and glucose from Thermo Fischer 
Scientific (Bridgewater, NJ, USA); human recombinant zinc insulin from P. 
pastoris (28.5 IU/mg) was purchased from Merck (Whitehouse, NJ, USA). All other 
chemicals were of reagent grade. 
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3.2.2. Investigation of conditions for the formation of CSNP 
The nanoparticles were prepared via ionic gelation according to the method 
adopted by Calvo et al [67]. A stock solution of chitosan (1.5mg/ml) was 
prepared in 1% acetic acid, and a stock solution of TPP (0.5mg/ml) using milli-Q 
water. A fixed volume of TPP was then added dropwise to different volumes of 
chitosan solutions to give various chitosan:TPP ratios (3:1, 4:1, 5:1, 6:1 and 7:1) 
under constant stirring at 500rpm in room temperature. The mixtures were 
stirred at the same speed for a further 20 minutes after all the TPP was added. 
The nanoparticles were prepared in three different pH values (2.9, 4.2 and 5.5) 
to determine the optimum pH for further studies. 
3.2.3. Formulation of insulin loaded boronic acid-functionalised chitosan-TPP 
nanoparticles 
The two different boronic acid- (FPBA and FTBA) chitosan conjugates 
(chitosan:boronic acid = 1:1) were dissolved in 1% acetic acid to a concentration 
of 1.5mg/ml and the pH adjusted to 4.2 using 1M NaOH. Insulin (dissolved in 
0.01N HCl) was mixed with TPP (0.5mg/ml) to give a final concentration of 
0.3mg/ml. The insulin-TPP solution was then added dropwise to the conjugate 
solutions under magnetic stirring to prepare the two nanoparticulate 
formulations – FPBAINP and FTBAINP – as described in the previous section. 
Control nanoparticle formulations were also prepared that did not contain any 
insulin and were labelled FPBANP and FTBANP.  
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3.2.4. Physicochemical characterisation of nanoparticles 
The size (z-average), polydispersity index (pdi) and charge (zeta potential) of 
the nanoparticles were assessed using a Zetasizer Nano ZS (Malvern, UK) 
equipped with a 4Mw He-Ne laser (633 nm). Each analysis was carried out at 
25ºC, performed in triplicate and the data expressed as mean ± standard 
deviation. The morphology and surface topography of nanoparticles were 
performed by a field emission scanning electron microscope (FESEM, Quanta 
400F, FEI Company, USA) under low vacuum and at a viewing voltage of 20.0 kV. 
After a 1:10 dilution with deionized water, a drop of freshly prepared 
nanoparticulate solution was placed onto an SEM imaging stub and left to air-dry 
at room temperature for 24 hours before viewing. 
3.2.5. HPLC analysis for insulin content 
The amount of insulin in the samples was detected using an Agilent HPLC system 
equipped with a UV detector. The HPLC parameters are as follows: 
 mobile phase - 0.1% aqueous TFA (A) and 0.1% TFA in acetonitrile (B) 
 gradient elution with the mobile phase starting with 75% of A and 
decreasing to 40% over 7 min 
 flow rate – 1 ml/min 
 injection volume – 20µl 
 detection wavelength – 214 nm 
 column – Agilent Zorbax 300SB-4.6 x 250 mm C18, with particle size of 5 
μm and pore size of 300 Å. 
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The calibration curve was constructed from pure insulin dissolved in 0.01N HCl 
at a range of 1 - 100µg/ml. 
3.2.6. Evaluation of encapsulation efficiencies of nanoparticles 
The encapsulation efficiency (EE%) of insulin within the nanoparticles was 
determined upon separation of the nanoparticles from the aqueous media 
containing free insulin by centrifugation at 14000 rpm for 20 min using a Beckman 
Coulter Microfuge 16 centrifuge (Beckman Coulter, USA). The amount of free 
insulin in the supernatant was measured using the above HPLC procedure by 
comparing peak area obtained with that from the calibration curve. The EE% for 
insulin was calculated as: 
EE% =  
total insulin in formulation − free insulin in supernatant
total insulin in formulation
 ×100% 
3.2.7. In vitro insulin release studies 
The amount of insulin released from the nanoparticles was studied in six 
different media – deionised water, glucose (1, 2 and 3mg/ml), fructose 
(0.002mg/ml) and glucose (2mg/ml)+fructose (0.002mg/ml). Several 100 µl 
replicas of FPBAINP and FTBAINP were placed in Eppendorf tubes containing 1 ml 
of the various release media and incubated at 37ºC with horizontal shaking at 
100 rpm on a WiseCube WIS-20, Precise Shaking Incubator. At predetermined 
time points, one of the seeded tubes was withdrawn and centrifuged at 14000 
rpm for 5 minutes using a Beckman Coulter Microfuge 16 centrifuge which was 
followed by injection of 20 μl of the supernatant into the HPLC system. The 
amount of insulin released in the respective media was computed by comparing 
peak area obtained with those from the calibration curve. 
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3.3. Results and Discussion 
3.3.1. Optimisation of conditions for CSNP preparation 
The size of colloidal systems is an important parameter that determines the 
systems’ ability to deliver drugs to the target site effectively. Particles larger 
than 1µm are too large to diffuse through the blood-brain barrier and hence 
remain at the site of injection. Smaller particles have a better propensity for 
diffusing across tissue and this property has found wide appeal to cancer 
researchers who aim to target cancerous cells with drug-loaded nanoparticles. 
Ideally, a particle size of 100 – 300nm is desirable for in vitro and in vivo studies 
[60]. Fig.3.1 shows the changes in the size of the CSNP of various chitosan:TPP 
ratios and in the three different pH conditions. 
 
Fig.3.1. Mean particle size of the nanoparticles as a function of chitosan-
TPP ratios in different pH conditions.  
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In all three pH, the size of the nanoparticles drops sharply from ratio 3:1 to 4:1 
before rising again at higher ratios. CSNP are formed by the crosslinking of 
positively charged chitosan chains with the negatively charged TPP ions. Chitosan 
chains become positively charged due to the protonation of their primary amine 
groups in acidic media (NH3
+), however, not all the amine groups protonate in 
solution. The overall degree of protonation increases as the amount of chitosan 
increases.  
At 3:1 ratio, it can be hypothesised that there were not enough cationic moieties 
within the chitosan polymer chains to manifest an overall positive charge on the 
nanoparticles. This relatively lower surface charge on the particles promotes 
attractive van der Waals forces between the particles as opposed to repulsion at 
higher surface charges. This consequently causes the particles to aggregate and 
hence register higher z-average readings. A ratio of chitosan to TPP of 4:1 
appears to be optimum for the retention of sufficient positively charged chitosan 
moieties (NH3
+) to effectively complex with the anionic TPP ions (P3O10
-) resulting 
in the quenching of the anionic charge contribution and formation of a strongly 
positive residually charged nanoparticles. As the nanoparticles have an overall 
strong positive charge, they repel each other and do not aggregate as in ratio 
3:1. At ratios higher than 5:1, it can be postulated that the amount of TPP is 
insufficient to provide requisite anionic charge density to effectively crosslink 
the chitosan chains and form stable nanocomplexes. This ultimately causes the 
nanoparticles to have the tendency to form aggregates. 
The size of the nanoparticles appears to vary according to the pH environment 
as well. In general, the particle size increases as the pH increases. At lower pH, 
there is effective crosslinking between the chitosan chains by the TPP to form 
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stable nanoparticles because there are very little OH- ions available in the 
medium. However, as the pH of the media is increased, more OH- ions are 
available in solution. Since OH- ions are much smaller than TPP ions, they can 
penetrate the chitosan gel matrix a lot more easily and hence compete with the 
TPP ions for interaction with the positively charged chitosan. Consequently, the 
nanoparticle matrix destabilises at higher pH resulting in an increase in the 
overall size of the particles. Mattu et al. [68] also obtained similar results in the 
size of their chitosan nanoparticles with an increase in pH of the medium and 
attributed this observation to the presence of increased OH- ions in solution. 
3.3.2. Preparation of insulin loaded nanoparticles 
After careful analysis of all the physicochemical parameters, and from a stability 
standpoint, chitosan:TPP ratio of 4:1 and a pH of 4.2 were chosen to be the 
optimum conditions for the preparation of insulin containing nanoparticles. 
Table 3.1 shows the size, charge and pdi of the various nanoparticle 
formulations. 
Formulae  Diameter (nm) Zeta potential (mV) Pdi 
CSNP 111.6 ± 2.3 59.0 ± 11.3 0.26 
FPBANP 147.4 ± 13.7 30.8 ± 7.9 0.32 
FPBAINP 170.1 ± 14.2  23.4 ± 4.5 0.31 
FTBANP 138.5 ± 5.9 27.9 ± 4.3 0.19 
FTBAINP 162.7 ± 9.8 22.2 ± 2.5 0.22 
Data shown are the mean ± standard deviation (n = 3). 
Table 3.1. Physicochemical parameters of the nanoparticulate formulations 
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Fig. 3.2. Physicochemical characteristics of the nanoparticulate 
formulations 
The general trend in size follows the order of BAINP > BANP > CSNP. Indeed the 
boronic acid chitosan conjugates are larger in structure than the native chitosan 
and hence results in the formation of larger insulin-free nanoparticles. The 
consumption of the amine groups of chitosan during the reductive N-alkylation 
to form the conjugates means that chitosan is less positively charged and hence 
the overall charge of the nanoparticles is lower. Insulin loaded nanoparticles are 
the largest because of the introduction of insulin molecule into the 
nanoparticulate matrix. The negative charge of insulin contributes to a slight 
reduction in the total charge of the nanoparticles as well.  
0
10
20
30
40
50
60
70
0
20
40
60
80
100
120
140
160
180
200
CSNP FPBANP FPBAINP FTBANP FTBAINP
C
h
a
rg
e
 (
m
V
)
P
a
rt
ic
le
 s
iz
e
 (
n
m
)
Nanoparticulate formulations
Particle size (nm) Charge (mV)
58 
 
  
(a) 
59 
 
  
(b)         
Fig.3.3. Scanning electron microphotography of (a) FPBAINP and (b) 
FTBAINP 
Overall, the average diameters of the target nanoparticles – FPBAINP and 
FTBAINP – are reasonably small and the formulations are homogenous (as 
indicated by the pdi value). Nanoparticles with a surface charge of |10| mV are 
considered approximately neutral; while nanoparticles with zeta potentials of at 
least |30| mV are considered strongly ionic, thereby ensuring sufficient repulsive 
forces to keep the particles apart [69]. In that respect, the overall charges of 
the formulations are slightly on the lower side. Notwithstanding, FPBAINP and 
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FTBAINP appear to be reasonably separated from each other as shown in the 
FESEM images in fig.3.2. The particles also appear spherical and in agreement 
with the z-average determinations. 
3.3.3. Percentage encapsulation efficiency (EE%) 
The drug release profile and pharmaceutical cost-effectiveness of a formulation 
depend on the drug loading capacity or the encapsulation efficiency (EE %) within 
the carrier system. This is particularly crucial for nanoparticulate delivery 
systems which have the smallest surface area-to-volume ratio of all dosage 
forms. The EE% for FPBAINP and FTBAINP were 56.7% and 57.5% respectively. 
Fig.3.3a and b show the chromatograph obtained from the HPLC analysis of an 
insulin standard and the calibration curve of the standards respectively. There is 
a range of reported EE% of insulin in nanoparticulate drug delivery systems. 
Zhang et al. [70] reported an insulin loading capacity of more than 78% in their 
polyethylene grafted chitosan nanoparticles, whilst Zhu et al. [71] prepared PEG 
modified N-trimethylaminoethylmethacrylate chitosan nanoparticles which 
resulted in a range of EE% from 10 – 84% depending on the initial weight of the 
polymer used in the formulation. Wu et al. [63] formulated nanoparticles with 
an EE% ranging from 49 – 59% and contend that this variability was attributed to 
the amount of insulin used and the molecular weight of the polymer. 
61 
 
 
(a) 
 
(b) 
Fig.3.4. (a) Chromatogram of insulin standard (100µg/ml) and (b) 
Calibration curve of insulin standards 
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We may conclude that the EE% obtained in the present investigation is 
comparable to those reported in the literature. One of the initial hypothesis for 
choosing FTBA as the glucose sensor was the presence of sulphur in its structure. 
It was assumed that sulphur would lead to a higher encapsulation of insulin into 
the nanoparticulate matrix via additional interactions with the disulphide 
bridges present in the structure of insulin. However, the EE% of FPBAINP, which 
lacks the sulphur atom, is comparable to that of FTBAINP which might imply that 
the sulphur (in FTBA) has little or no effect in additional insulin encapsulation in 
the present scenario. 
3.3.4. In vitro insulin release in various media 
The primary objective of this project is to formulate an insulin delivery system 
that is glucose sensitive. In chapter 2, we have proven the superior selectivity of 
FPBA- and FTBA-chitosan conjugates (at BA:chitosan ratio of 1:1) for glucose 
compared to fructose by discussing the chemistry of the conjugates in the 
presence of the diols. The current chapter further substantiates the selectivity 
of the two conjugates for glucose by the physiochemical behaviour of the 
nanoparticulate formulations of the conjugates. To prove our theory, FPBAINP 
and FTBAINP were exposed to different media. Three different blood 
concentrations of glucose were used to test the glucose dependent release of 
insulin. Deionised water was used to check the leaking of the nanoparticles. A 
blood concentration (diabetic) of fructose only was used to check how much 
insulin was released and another media had both glucose and fructose of 
concentrations similar to that in the blood of a diabetic patient to check the 
amount of insulin released. Fig.3.4a and b show the insulin release profiles of 
the two nanoparticle formulations in the six different media used. 
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In FPBAINP (fig.3.4a), an initial burst phase of insulin release followed by a more 
sustained release was observed in all media. The burst phase can be attributed 
to the release of insulin that is entrapped toward the edge of the nanoparticulate 
matrix. The sustained release is of the insulin that is present within the deeper 
pockets of the core matrix. However, the amount of insulin released during the 
burst phase varied depending on the external media.  
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(b) 
Fig. 3.5. Insulin release profiles of (a) FPBAINP and (b) FTBAINP in various 
media 
A similar pattern of insulin release was observed in FTBAINP formulation as well. 
In both FPBAINP and FTBAINP, the amount of insulin released within the first 10–
20 minutes increased as the concentration of external glucose media increased 
from 1 – 3mg/ml. In fact, within the first 20 mins the amount of insulin released 
from both the formulations in glucose media (3mg/ml) was at least twice that in 
glucose media (1mg/ml). Springsteen et al. [51] noted that at higher glucose 
concentrations, the rate of interaction between glucose and boronic acid is 
higher; hence a faster rate of insulin release occurred in this instance. This 
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behaviour of our systems proves their glucose concentration dependent insulin 
release potential. 
Not only are the EE% of the two formulations similar, but the total amount of 
insulin released after one hour is also almost equal in FPBAINP and FTBAINP. Both 
formulations have minimal leakage as the total amount of insulin released after 
one hour is below 4%.  
Interestingly, the total amount of insulin released from FPBAINP in fructose is 
higher than that released from FTBAINP in the same media. This observation 
might be the result of fewer interactions between fructose and FTBA moieties 
than with FPBA moieties and hence allude to the fact that FTBA has lower affinity 
for fructose than FPBA. This implication will be of significant advantage in 
developing a GRID; however, it is imperative to conduct further investigations 
before any assertion is made.  
It should also be noted that the amount of insulin released from both the 
formulations in fructose (of blood concentration) is similar to that released in 
deionised water and/or glucose (1mg/ml). Furthermore, in glucose+fructose 
media, the total amount of insulin released from both the systems is similar to 
that released in 2mg/ml glucose media. Considering the fact that both media 
had the same concentration of glucose and the only difference was the (blood 
concentration) of fructose, it can be contended that both FPBAINP and FTBAINP 
are glucose selective in physiological settings. The presence of minute amounts 
of fructose (which is similar to that in human blood) does not appear to have a 
marked effect in insulin release from the two systems. These observations 
further validate the theory discussed in chapter 2 about the stronger multivalent 
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bindings between the boronic acid conjugated chitosan with glucose than the 
monovalent interactions with fructose and hence confirm the higher selectivity 
of the conjugates for glucose than for fructose in biological conditions. 
3.4. Conclusions 
Two different boronic acid conjugated chitosans have been formulated into 
insulin loaded nanoparticles. The formulations were then investigated for their 
physicochemical properties and insulin release in various media. The 
nanoparticles in both the formulations were small, reasonably charged and 
homogenous promising good stability. The EE% of insulin of both FPBAINP and 
FTBAINP were similar and comparable to those published in the literature. Both 
the systems released insulin predominantly in the presence of glucose and show 
great potential to be successful GRIDs. 
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FUTURE WORK 
In this project, a chitosan-based nanoparticulate GRID system has been 
developed and its potential has been studied via various investigations. However, 
for approval of clinical trials, further experiments need to be carried out and 
some of these include the following: 
 Preparation of a larger set of boronic acid-chitosan conjugate ratios and 
characterisation of their selectivity for diols as a function of the degree 
of boronic acid conjugation to chitosan 
 Formulation of insulin-loaded chitosan nanoparticles at physiological pH 
 Cytotoxicity and biocompatibility studies of the nanoparticles 
 Stability studies of the nanoparticles 
 In vitro insulin release studies for a longer period of time to determine 
the lifetime of the formulated GRID system 
 In vivo studies to investigate the potential of the GRID 
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